Ignite Creation Date:
2025-12-24 @ 5:17 PM
Ignite Modification Date:
2025-12-27 @ 3:58 AM
Study NCT ID:
NCT07210450
Status:
COMPLETED
Last Update Posted:
2025-10-07
First Post:
2025-09-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia
Sponsor:
Mazandaran University of Medical Sciences
Organization:
Study Overview
Official Title:
The Effect of Glutamine on Reducing Pulmonary Arterial Pressure in Non-transfusion-dependent Thalassemia Patients: a Single Blind Randomized Clinical Trial
Status:
COMPLETED
Status Verified Date:
2025-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to learn whether L-glutamine can help lower pulmonary artery pressure in adults with non-transfusion-dependent thalassemia (NTDT).
The main questions it aims to answer are:
Does L-glutamine reduce pulmonary artery pressure after 60 days of treatment?
Is the effect of L-glutamine different from standard care alone?
Researchers will compare two groups:
Intervention group: Participants receive oral L-glutamine in addition to their standard treatment.
Control group: Participants continue with standard treatment only.
Participants will:
Take either L-glutamine (by mouth) or standard care for 60 days. Undergo echocardiography at the beginning and end of the study to measure pulmonary artery pressure.
Attend follow-up visits to monitor safety, adherence, and possible side effects.
The main questions it aims to answer are:
Does L-glutamine reduce pulmonary artery pressure after 60 days of treatment?
Is the effect of L-glutamine different from standard care alone?
Researchers will compare two groups:
Intervention group: Participants receive oral L-glutamine in addition to their standard treatment.
Control group: Participants continue with standard treatment only.
Participants will:
Take either L-glutamine (by mouth) or standard care for 60 days. Undergo echocardiography at the beginning and end of the study to measure pulmonary artery pressure.
Attend follow-up visits to monitor safety, adherence, and possible side effects.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: